Eloralintide is an , once-weekly selective amylin receptor agonist developed by Eli Lilly and Company that mimics the natural pancreatic hormone amylin to regulate appetite, slow gastric emptying, and improve cardiometabolic markers in people with obesity or overweight. 

Weight Loss and Satiety

• Substantial weight reduction: Phase 2 clinical trials showed participants achieved body weight reductions ranging from 9% to over 20% across 48 weeks depending on the dosage.

• Appetite suppression: It acts on brainstem and central nervous system pathways to promote feelings of fullness and reduce food intake.

• Delayed gastric emptying: Slows down the rate at which food leaves the stomach, prolonging post-meal satisfaction.

Cardiometabolic and Physiological Effects

• Improved lipid profiles: Demonstrates favorable reductions in triglycerides and low-density lipoprotein cholesterol.

• Reduced inflammation: Lowers high-sensitivity C-reactive protein concentrations.

• Resting heart rate reduction: Unlike many GLP-1 receptor agonists that can induce a modest increase in heart rate, eloralintide has been noted to lower resting heart rate.